$BIOCON

$BIOCON strengthened its Malaysia presence after partner Duopharma secured insulin contracts worth over ₹514 crore, ensuring affordable diabetes treatment and expanding patient access. The contracts reinforce Biocon's position in the global insulin market, support long-term revenue visibility, and highlight its commitment to improving healthcare accessibility.